XNAS · Healthcare · Biotechnology
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-05 | Q1 2026 | -1.00 | -1.11 | -11.00% | $6.6M | ❌ Miss | +0.00% | -2.36% | — |
| 2026-02-17 | Q4 2025 | -0.98 | -0.94 | +4.08% | $10.9M | ✅ Beat | +0.52% | +4.26% | +5.98% |
| 2025-11-04 |
| Q3 2025 |
| -0.55 |
| 1.33 |
| +341.82% |
| $207.8M |
| ✅ Beat |
| — |
| — |
| — |
| 2025-08-05 | Q2 2025 | -0.82 | -0.88 | -7.32% | $0 | ❌ Miss | +3.96% | -2.20% | +7.09% |
| 2025-02-13 | Q4 2024 | -0.61 | -1.49 | -144.26% | $7.0M | ❌ Miss | +1.16% | +4.67% | -7.85% |
| 2024-11-04 | Q3 2024 | -0.67 | -0.60 | +10.45% | $0 | ✅ Beat | -1.40% | +6.60% | -5.50% |
| 2024-08-06 | Q2 2024 | -0.54 | -0.68 | -25.93% | $0 | ❌ Miss | -0.39% | +6.06% | +3.81% |
| 2024-05-07 | Q1 2024 | -0.51 | -0.53 | -3.92% | $0 | ❌ Miss | -3.13% | -2.22% | -7.30% |
Showing last 8 quarters.